News|Articles|July 2, 2026

Allergy First Half Recap: 2026

Fact checked by: Tim Smith

A roundup of key FDA approvals, pipeline advances, and updated guidelines shaping allergy and HAE care in the first half of 2026.

Allergy and immunology saw significant regulatory momentum in the first half of 2026, headlined by new approvals in allergic fungal rhinosinusitis (AFRS), pediatric hereditary angioedema (HAE), and epinephrine access, alongside pipeline advances in systemic mastocytosis and HAE. Updated international guidelines further refined first-line treatment strategies for pediatric HAE and epinephrine use in anaphylaxis.